Mona Marin

Mona Marin

Auto-generated profile, based on publicly available information

Mona Marin

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2007
Verified
Journal Article
Closed access
MMMona Marin
Mona Marin
DGDalya Güris
Dalya Güris
SCSandra S. Chaves
Sandra S. Chaves
SSScott Schmid
Scott Schmid
JSJane F Seward
Jane F Seward

1 March 2016 in Pediatrics
Verified
Journal Article
Open access
PDF file
MMMona Marin
Mona Marin
Melanie MartiMelanie Marti
Melanie Marti
AKAnita Kambhampati
Anita Kambhampati
SJStanley M. Jeram
Stanley M. Jeram
JSJane F. Seward
Jane F. Seward
CONTEXT: Several varicella vaccines are available worldwide. Countries with a varicella vaccination program use 1- or 2-dose schedules. OBJECTIVE: We examined postlicensure estimates of varicella vaccine effectiveness (VE) among healthy children. DATA SOURCES: Systematic review and descriptive and meta-analysis of Medline, Embase, Cochrane libraries, and CINAHL databases for reports published during 1995–2014. STUDY SELECTION: Publications that reported original data on dose-specific varicella VE among immunocompetent children. DATA EXTRACTION: We used random effects meta-analysis models to obtain pooled one dose VE estimates by disease severity (all varicella and moderate/severe varicella). Within each severity category, we assessed pooled VE by vaccine and by study design. We used descriptive statistics to summarize 1-dose VE against severe disease. For 2-dose VE, we calculated pooled estimates against all varicella and by study design. RESULTS: The pooled 1-dose VE was 81% (95% confidence interval [CI]: 78%–84%) against all varicella and 98% (95% CI: 97%–99%) against moderate/severe varicella with no significant association between VE and vaccine type or study design (P > .1). For 1 dose, median VE for prevention of severe disease was 100% (mean = 99.4%). The pooled 2-dose VE against all varicella was 92% (95% CI: 88%–95%), with similar estimates by study design. LIMITATIONS: VE was assessed primarily during outbreak investigations and using clinically diagnosed varicella. CONCLUSIONS: One dose of varicella vaccine was moderately effective in preventing all varicella and highly effective in preventing moderate/severe varicella, with no differences by vaccine. The second dose adds improved protection against all varicella.

1 September 2008 in Pediatrics
Verified
Journal Article
Closed access
MMMona Marin
Mona Marin
HMH. Cody Meissner
H. Cody Meissner
JSJane F. Seward
Jane F. Seward
OBJECTIVE. In 1995, the United States was the first country to introduce a universal 1-dose childhood varicella vaccination program. In 2006, the US varicella vaccine policy was changed to a routine 2-dose childhood program, with catchup vaccination for older children. The objective of this review was to summarize the US experience with the 1-dose varicella vaccination program, present the evidence considered for the policy change, and outline future challenges of the program.METHODS. We conducted a review of publications identified by searching PubMed for the terms “varicella,” “varicella vaccine,” and “herpes zoster.” The search was limited to US publications except for herpes zoster; we reviewed all published literature on herpes zoster incidence.RESULTS. A single dose of varicella vaccine was 80% to 85% effective in preventing disease of any severity and >95% effective in preventing severe varicella and had an excellent safety profile. The vaccination program reduced disease incidence by 57% to 90%, hospitalizations by 75% to 88%, deaths by >74%, and direct inpatient and outpatient medical expenditures by 74%. The decline of cases plateaued between 2003 and 2006, and outbreaks continued to occur, even among highly vaccinated school populations. Compared with children who received 1 dose, in 1 clinical trial, 2-dose vaccine recipients developed in a larger proportion antibody titers that were more likely to protect against breakthrough disease and had a 3.3-fold lower risk for breakthrough disease and higher vaccine efficacy. Two studies showed no increase in overall herpes zoster incidence, whereas 2 others showed an increase.CONCLUSIONS. A decade of varicella prevention in the United States has resulted in a dramatic decline in disease; however, even with high vaccination coverage, the effectiveness of 1 dose of vaccine did not generate sufficient population immunity to prevent community transmission. A 2-dose varicella vaccine schedule, therefore, was recommended for children in 2006. Data are inconclusive regarding an effect of the varicella vaccination program on herpes zoster epidemiology.

1 August 2011 in Pediatrics
Verified
Journal Article
Closed access
MMMona Marin
Mona Marin
JZJohn X. Zhang
John X. Zhang
JSJane F. Seward
Jane F. Seward
OBJECTIVE: Varicella has been preventable by vaccination in the United States since 1995. Previous studies reported a 66% decline in mortality rate during the first 6 years of the program. Since then, vaccination coverage has increased substantially. We updated the analysis of US varicella mortality for 2002–2007 and assessed the impact of the first 12 years of the US varicella vaccination program on varicella deaths.METHODS: National data on deaths for which varicella was listed as an underlying or contributing cause were obtained from the Mortality Multiple Cause-of-Death records from the US National Center for Health Statistics. We calculated the age-adjusted and age-specific mortality rates for 2002–2007 and trends since the prevaccine years.RESULTS: During the 12 years of the mostly 1-dose US varicella vaccination program, the annual average mortality rate for varicella listed as the underlying cause declined 88%, from 0.41 per million population in 1990–1994 to 0.05 per million population in 2005–2007. The decline occurred in all age groups, and there was an extremely high reduction among children and adolescents younger than 20 years (97%) and among subjects younger than 50 years overall (96%). In the last 6 years analyzed (2002–2007), a total of 3 deaths per age range were reported among children aged 1 to 4 and 5 to 9 years, compared with an annual average of 13 and 16 deaths, respectively, during the prevaccine years.CONCLUSIONS: The impressive decline in varicella deaths can be directly attributed to successful implementation of the 1-dose vaccination program. With the current 2-dose program, there is potential that these most severe outcomes of a vaccine-preventable disease could be eliminated.

1 July 2008 in Vaccine
Verified
Journal Article
Closed access
MMMona Marin
Mona Marin
PQPatricia Quinlisk
Patricia Quinlisk
TSTom Shimabukuro
Tom Shimabukuro
CSCharu Sawhney
Charu Sawhney
CBCedric Brown
Cedric Brown
CLCharles W. LeBaron
Charles W. LeBaron

1 March 2008 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MMMona Marin
Mona Marin
TWTureka L. Watson
Tureka L. Watson
SCSandra S. Chaves
Sandra S. Chaves
RCRachel Civen
Rachel Civen
BWBarbara M. Watson
Barbara M. Watson
JSJane F. Seward
Jane F. Seward
We report detailed population-based data on varicella among adults. In 2 US varicella active surveillance sites with high vaccine coverage among youn